Conference Coverage

Severe OA sparks depression, surgery “ameliorates” depression in RA


 

REPORTING FROM THE EULAR 2018 CONGRESS

Depression “ameliorated” by orthopedic surgery for RA

While the effects of analgesic medications might be something to look at in relation to depression in OA, research presented elsewhere at the congress suggested that appropriate surgical intervention might also be key to dealing with depressive symptoms, at least in patients with RA.

After a 1-year follow-up in patients with RA who underwent orthopedic surgery, the mean BDI-II score improved from 13.0 to 11.5 (P less than .01), and the percentage of patients with a BDI-II score of 14 or more fell from 43% to 35%. Improvements in other health assessments – the Japanese version of the Health Assessment Questionnaire and the EuroQol 5 dimensions instrument – were also seen.

The prospective, observational cohort study included 276 patients with structural damage caused by RA. The most common site of joint damage requiring elective surgery was the wrist (n = 74), followed by the hand (n = 63), knee (n = 50), forefoot (n = 50), elbow (n = 26), hand and wrist (n = 18), hip (n = 13), ankle (n = 12), and shoulder (n = 6).

Looking at the improvement in depression scores by surgical site revealed a significant difference from baseline for the elbow (P less than .001), wrist (P less than .001), and forefoot (P less than .05). The magnitude of decrease in the BDI-II scores was independently related to Steinbrocker stage and pain measured on a visual analog scale.

“Depression was ameliorated by surgical intervention in patients with RA,” Hajime Ishikawa, MD, PhD, of the department of rheumatology at Niigata Rheumatic Center in Shibata, Japan, and associates concluded in their poster presentation. They added that the psychological changes observed were “related to the preoperative severity of joint damage and pain in the affected joint.”

Dr. Rathbun’s work was supported by a Rheumatology Research Foundation Scientist Development Award. Dr. Ishikawa and associates stated they had no disclosures of interest.

SOURCES: Rathbun AM et al. Ann Rheum Dis. 2018;77(Suppl 2):50-1. Abstract OP0003; Ishikawa H et al. Ann Rheum Dis. 2018;77(Suppl 2):297-8. Abstract THU0156.

Pages

Recommended Reading

‘Bright future’ for growth factor therapy in osteoarthritis
MDedge Internal Medicine
Sprifermin moves FORWARD with sustained effects in osteoarthritis
MDedge Internal Medicine
Surgery may be best option for hip impingement syndrome
MDedge Internal Medicine
Cannabidiol gel for osteoarthritis knee pain gives lukewarm results
MDedge Internal Medicine
Novel x-ray score distinguishes psoriatic arthritis from osteoarthritis of the hand
MDedge Internal Medicine
New device could noninvasively detect osteoarthritis using sound and motion
MDedge Internal Medicine
Disease burden higher in osteoarthritis than rheumatoid arthritis
MDedge Internal Medicine
Prior knee injury osteoarthritis ‘distinct subgroup’
MDedge Internal Medicine
Post-traumatic osteoarthritis needs to be prevention focus
MDedge Internal Medicine
Hip pain predicts OA mortality beyond comorbidities
MDedge Internal Medicine